Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Equity Average (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Equity Average data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Equity Average rose 2108.6% year-over-year to $3.9 million; the TTM value through Oct 2025 reached $3.9 million, up 2108.6%, while the annual FY2025 figure was $934500.0, 31.61% down from the prior year.
  • Equity Average reached $3.9 million in Q4 2025 per CSBR's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $9.2 million in Q2 2022 and bottomed at -$2.0 million in Q2 2024.
  • Average Equity Average over 5 years is $4.8 million, with a median of $5.2 million recorded in 2023.
  • Peak YoY movement for Equity Average: tumbled 134.18% in 2024, then surged 2108.6% in 2025.
  • A 5-year view of Equity Average shows it stood at $7.8 million in 2021, then grew by 16.31% to $9.1 million in 2022, then plummeted by 89.01% to $998000.0 in 2023, then plummeted by 82.52% to $174500.0 in 2024, then soared by 2108.6% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $3.9 million in Q4 2025, $3.7 million in Q3 2025, and $4.6 million in Q2 2025.